Reference
- Welsby IJ, Bennett-Guerrero E, Atwell D, White WD, Newman MF, Smith
PK, Mythen MG. The association of complication type with mortality and
prolonged stay after cardiac surgery with cardiopulmonary bypass.
Anesth Analg 2002;94:1072—8.
- Bouza E, Hortal J, Munoz P, Pascau J, Perez MJ, Hiesmayr M, European
Study Group on Nosocomial Infections, European Workgroup of
Cardiothoracic Intensivists. Postoperativeinfections after major heart
surgery and prevention of ventilator-associated neumonia: a one-day
European prevalence study (ESGNI-008). J Hosp Infect 2006;64:224—30.
- Michalopulos A, Geroulanos S, Rosmarakis ES, Falagas ME. Frequency,
characteristics, and redictors of microbiologically documented
nosocomial infections after cardiac surgery. Eur J Cardiothorac Surg
2006;2:456—60.
- De Santo LS, Romano G, Amarelli C, Onorati F, Torella M, Renzulli
A,Galdieri N, Cotrufo M. Surgical repair of acute type A aortic
dissection: continuous pulmonary perfusion during retrograde cerebral
perfusion prevents lung injury in a pilot study. J Thorac Cardiovasc
Surg 2003;126:826—31.
- Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjet R. Guidelines for
preventing health-care-associated pneumonia 2003:recommendations of
CDC and the Healthcare Infection Control Practices Advisory Committee.
MMWR Recomm Rep 2004;53:1—36.
- Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions
for nosocomial infections, 1988. Am J Infect Control 1988;16:128—40.
- Horan TC, Gaynes RP. Surveillance of nosocomial infections. In:
Mayahall CG, editor. Hospital epidemiology and infection control.
Philadelphia: Lippincot Williams & Wilkins 2004. p. 1659—702.
- ATS Board of Directors. In: Guidelines for the management of adults
with hospital-acquired, ventilator-associated, and
healthcare-associated pneumonia. Am J Respir Crit Care Med
2005;171:388—416.
- Magiorakos AP,Srinivasan A,Carey RB, et al.
Multidrug-resistant,extensively drug-resistant and pandrug-resistant
bacteria: an international expert proposal for interim standard
definitions for acquired resistance. Clin Microbiol Infect
2012;18(3):268-281.
- Doi Y, Murray GL, Peleg AY. Acinetobacter baumannii: evolution of
antimicrobial resistance-treatment options. Semin Respir Crit Care Med
2015;36(1):85–98
- Tal-JasperR,KatzDE,Amrami N, etal. Clinical and epidemiologic.al
significance of Carbapenem resistance in Acinetobacter baumannii
infections. Antimicrob Agents Chemother 2016;60(5):3127–3131.
- Gavaldà L, Soriano AM, Cámara J, et al. Control of endemic extensively
drug-resistant Acinetobacter baumannii with a cohorting policy and
cleaning procedures based on the 1 room, 1wipe approach. Am J Infect
Control 2016;44(5):520–524.
- Doi Y, Murray GL, Peleg AY. Acinetobacter baumannii: evolution of
antimicrobial esistance-treatment options. Semin Respir Crit Care Med
2015;36(1):85–98.
- Wisplinghoff H, Paulus T, Lugenheim M, et al. Nosocomial bloodstream
infections due to Acinetobacter baumannii, Acinetobacter pittii and
Acinetobacter nosocomialis in the United States. J Infect
2012;64(3):282-290.
- Vincent JL, Rello J, Marshall J, et al; EPIC II Group of
Investigators.International study of the prevalence and outcomes of
infection in intensive care units. JAMA 2009;302(21):2323–2329.
- Kempf M, Rolain JM. Emergence of resistance to carbapenems in
Acinetobacter baumannii in Europe: clinical impact and therapeutic
options. Int J Antimicrob Agents 2012;39(2):105–114.
- Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS.
Ampicillin/sulbactam compared with polymyxins for the treatment of
infections caused by carbapenem-resistant Acinetobacter spp. J
Antimicrob Chemother 2008;61(6):1369–1375.
- Jaruratanasirikul S, Wongpoowarak W, Aeinlang N, Jullangkoon M.
Pharmacodynamics modeling to optimize dosage regimens of sulbactam.
Antimicrob Agents Chemother 2013;57(7):3441–3444.
- Lob SH, Hoban DJ, Sahm DF, Badal RE. Regional differences and
trends in antimicrobial susceptibility of Acinetobacter baumannii. Int J
Antimicrob Agents 2016;47(4):317–323.
- BuissonY, TranVanNhieuG, GinotL, etal. Nosocomial outbreaks due
to amikacin-resistant tobramycin-sensitive Acinetobacter species:
correlation with amikacin usage. J Hosp Infect 1990;15(1):83–93.
- Vincent, Jean-Louis. Nosocomial infection in the ICU. Microbes
and Infection 2004;6(11):1003-1007.
- Ma CF, Li FQ, Shi LN, Hu YA, Wang Y, Huang M, Kong QQ.
Surveillance study of species distribution, antifungal susceptibility
and mortality of nosocomial candidemia in a tertiary care hospital in
China. BMC Infect Dis 2013; 13(1): 337.
- Poikonen E, Lyytikäinen O, Anttila VJ, Koivula I, Lumio
J,Kotilainen P, Syrjälä H, Ruutu P. Secular trend in candidemia and the
use of fluconazole in Finland, 2004–2007. BMC Infect Dis 2010; 10(1):
312.
- Miceli MH, Díaz JA, Lee SA. Emerging opportunistic yeast
infections. Lancet Infect Dis 2011; 11(2): 142–151.
- Gavaldà J, Meije Y, Fortún J, Roilides E, Saliba F, Lortholary
O, Muñoz P, Grossi P, uenca-Estrella M; ESCMID Study Group for
Infections in Compromised Hosts. Invasive fungal infections in solid
organ transplant recipients. Clin Microbiol Infect 2014; 20 (Suppl 7):
27–48.
- Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White
TC. Hidden killers: human fungal
infections. Sci Transl Med 2012; 4(165): 163-165.
- Gao LY, Yu J, Li RY. Epidemiology of aspergillosis in mainland
China. Chin J Mycol (Zhongguo Zhen Jun Xue Za Zhi) 2010; 5(4): 247–251
(in Chinese)